{
    "nctId": "NCT00031278",
    "briefTitle": "Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer",
    "officialTitle": "A Phase I/II Open Label, Multi-Center Study For The Evaluation Of The Combination Of CpG 7909 And Herceptin\u00ae In Patients With Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Carcinoma, Metastatic Breast",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 12,
    "primaryOutcomeMeasure": "Phase I: To evaluate the safety, tolerability and and MTD of several dose levels of CPG 7909 of CPG 7909 in combination with the standard Herceptin\u00ae treatment in patients with metastatic breast cancer",
    "eligibilityCriteria": "INCLUSION CRITERIA Inclusion Criteria\n\n* Histologically confirmed breast cancer with metastases.\n* Tumor that has overexpression of HER2 as documented by being either FISH-positive or HER2/neu 3+ confirmed by immunohistochemistry.\n* Patients must be candidates for single agent Herceptin treatment according to the Herceptin\u00ae label.\n\nExclusion Criteria\n\n* Any prior therapy with anthracycline + Herceptin\u00ae.\n* Significant cardiovascular disease (e.g., NYHA class 3 congestive heart failure, myocardial infarction within the past 6 months, unstable angina; coronary angioplasty within the past 6 months, uncontrolled atrial or ventricular cardiac arrhythmias) or left ventricular ejection fraction \\< 50%.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}